Literature DB >> 17241289

Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1).

R M Tordera1, S Totterdell, S M Wojcik, N Brose, N Elizalde, B Lasheras, J Del Rio.   

Abstract

Three isoforms of a vesicular glutamate transporter (VGLUT1-3) have been identified. Of these, VGLUT1 is the major isoform in the cerebral cortex and hippocampus where it is selectively located on synaptic vesicles of excitatory glutamatergic terminals. Variations in VGLUT1 expression levels have a major impact on the efficacy of glutamate synaptic transmission. Given evidence linking alterations in glutamate neurotransmission to various neuropsychiatric disorders, we investigated the possible influence of a down-regulation of VGLUT1 transporter on anxiety, depressive-like behaviour and learning. The behavioural phenotype of VGLUT1-heterozygous mice (C57BL/6) was compared to wild-type (WT) littermates. Moreover, VGLUT1-3 expression, hippocampal excitatory terminal ultrastructure and neurochemical phenotype were analysed. VGLUT1-heterozygous mice displayed normal spontaneous locomotor activity, increased anxiety in the light-dark exploration test and depressive-like behaviour in the forced swimming test: no differences were shown in the elevated plus-maze model of anxiety. In the novel object recognition test, VGLUT1(+/-) mice showed normal short-term but impaired long-term memory. Spatial memory in the Morris water maze was unaffected. Western blot analysis confirmed that VGLUT1 heterozygotes expressed half the amount of transporter compared to WT. In addition, a reduction in the reserve pool of synaptic vesicles of hippocampal excitatory terminals and a 35-45% reduction in GABA in the frontal cortex and the hippocampus were observed in the mutant mice. These observations suggest that a VGLUT1-mediated presynaptic alteration of the glutamatergic synapses, in specific brain regions, leads to a behavioural phenotype resembling certain aspects of psychiatric and cognitive disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17241289     DOI: 10.1111/j.1460-9568.2006.05259.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  63 in total

Review 1.  Contribution of Vesicular Glutamate Transporters to Stress Response and Related Psychopathologies: Studies in VGluT3 Knockout Mice.

Authors:  Hanga Réka Horváth; Csilla Lea Fazekas; Diána Balázsfi; Subodh Kumar Jain; József Haller; Dóra Zelena
Journal:  Cell Mol Neurobiol       Date:  2017-08-03       Impact factor: 5.046

2.  Chronic variable stress impairs energy metabolism in prefrontal cortex and hippocampus of rats: prevention by chronic antioxidant treatment.

Authors:  Bárbara Tagliari; Cristie G Noschang; Andréia G K Ferreira; Otávio A Ferrari; Luciane R Feksa; Clovis M D Wannmacher; Carla Dalmaz; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2010-05-27       Impact factor: 3.584

Review 3.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 4.  Glutamate transporters in brain ischemia: to modulate or not?

Authors:  Weronika Krzyżanowska; Bartosz Pomierny; Magłorzata Filip; Joanna Pera
Journal:  Acta Pharmacol Sin       Date:  2014-03-31       Impact factor: 6.150

Review 5.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

6.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 7.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

8.  Effective Mechanism for Synthesis of Neurotransmitter Glutamate and its Loading into Synaptic Vesicles.

Authors:  Kouji Takeda; Tetsufumi Ueda
Journal:  Neurochem Res       Date:  2016-08-26       Impact factor: 3.996

9.  Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Authors:  Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

Review 10.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.